Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of esketamine in opioid-resistant cancer pain
ChiCTR2200064343Phase 4Not yet recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in cancer pain (2 arms), sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoints: Pain VAS score and Opioid dosage. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2200064343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064343.